CORT Latest Press Releases

-- November 4, 2025 --

Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update Business Wire 4:05 PM

-- October 28, 2025 --

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call Business Wire 4:05 PM

-- October 19, 2025 --

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment Business Wire 5:15 AM

-- October 14, 2025 --

Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer Business Wire 8:00 AM

-- September 22, 2025 --

Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025 Business Wire 2:30 PM

-- September 10, 2025 --

FDA Files Corcept's New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer Business Wire 8:00 AM

-- July 31, 2025 --

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update Business Wire 4:05 PM

-- July 24, 2025 --

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call Business Wire 4:05 PM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software